Dietary cardamom inhibits the formation of azoxymethaneinduced aberrant crypt foci in mice and reduces COX-2 and inos expression in the colon

Asian Pacific Journal of Cancer Prevention

Volumn 6, Issue 2, 2005, Pages 118-122

  Sengupta, Archana ^a   Ghosh, Samit ^a   Bhattacharjee, Shamee ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Aberrant crypt foci; Azoxymethane; Cardamom; COX 2; iNOS

Indexed keywords

ANTINEOPLASTIC AGENT; AZOXYMETHANE; CARCINOGEN; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; NOS2 PROTEIN, MOUSE; PROSTAGLANDIN SYNTHASE;

ANIMAL; APOPTOSIS; ARTICLE; CARDAMOM; CHEMICALLY INDUCED DISORDER; COLON DISEASE; COLON TUMOR; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MOUSE; PRECANCER; RANDOMIZATION; WESTERN BLOTTING;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; AZOXYMETHANE; BLOTTING, WESTERN; CARCINOGENS; COLONIC DISEASES; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; ELETTARIA; MICE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PRECANCEROUS CONDITIONS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RANDOM ALLOCATION;

EID: 24944458215     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. al-Zuhair H, el-Sayeh B, Ameen HA, al-Shoora H. (1996). Pharmacological studies of cardamom oil in animals. Pharmacol Res, 34, 79-82.
2. Ann M Bode, Wei-Ya Ma, Young-Joon Surh, Zigang Dong. (2001). Inhibiton of epidermal growth factor-induced cell transformation and activator protein-1 activation by [6]-Gingerol, Cancer Res, 61, 850-3.
3. Asamoto M, et al. (2002). Mammary carcinomas induced in human c-Ha-ras protooncogene transgenic rats are estrogenindependent, but responsive to d-limonene treatment. Jpn J Cancer Res, 93, 32-5.
4. Barrachina MD, Panes J, Esplugues JV. (2001). Role of nitric oxide in gastrointestinal inflammatory and ulcerative diseases: perspective for drugs development. Curr Pharm Des, 7, 31-48.
5. Bedi A, Pasricha PJ, Akhtar AJ, et al. (1995). Inhibition of apoptosis during development of colorectal cancer. Cancer Res, 55, 1811-6.
6. Belanger JT. (1998). Perillyl alcohol:Applications in oncology. Altern Med Rev, 3, 448-57.
7. Bird RP. (1987). Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett, 37, 147-51.
8. Bird RP. (1995). Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett, 93, 55-71.
9. Caderni C, DeFilippo C, Luceri C, et al. (2000). Effects of black tea, green tea and wine extracts on intestinal carcinogenesis induced by azoxymethane in F344 rats. Carcinogenesis, 21, 1965-9.
10. Crowell PL, et al. (1994). Human metabolism of the experimental cancer therapeutic agent d-limonene. Cancer Chemother Pharmacol, 35, 31-7.
11. Dashwood RH. (1999). Early detection and prevention of colorectal cancer (review). Oncol Rep, 6, 277-81.
12. Davidson LA, Brown RE, Chang WL, et al. (2000). Morphodensitometric analysis of protein kinase C bII expression in rat colon: modulation by diet and relation to in situ cell proliferation and apoptosis. Carcinogenesis, 21, 1513-9.
13. Ferrandez A, Prescott S, Burt RW. (2003). COX-2 and colorectal cancer. Curr Pharm Des. 9, 2229-51.
14. Greenlee RT, Murray T, Bolden S, Wingo PA. (2000). Cancer statistics. CA Cancer J Clin, 50, 7-33.
15. Gupta SK, Ed. (2001). Pharmacology & Therapeutics in the New Millenium. New Delhi : Narosa Publishing House, pp345-354.
16. Hudes GR, et al. (2000). Phase I pharmacokinetics trial of perillyl alcohol (NSC 6410066) in patients with refractory solid malignancies. Clin Cancer Res, 6, 3071-80.
17. Jenab M, Thompson LU. (2001). Phytic acid in wheat bran affects colon morphology, cell differentiation and apoptosis. Carcinogenesis, 21, 1547-52.
18. Kaji I, et al. (2001). Inhibition by d- limoene of experimental hepatocarcinogenesis in Sprague- Dawley rats does not involve p21 (ras) plasma membrane association. Int J Cancer, 93, 441-4.
19. Krishnaswamy K, Polasa K. (2001). Nonnutrients and Cancer prevention, ICMR Bulletin Vol. 31.
20. Laemmli UK. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4 . Nature (London), 227, 680-5.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with Folin Phenol Reagent. J Biol Chem, 193, 265 - 75.
22. Marletta MA. (1993). Nitric oxide synthase structure and mechanism. J Biol Chem, 268, 12231-4.
23. McLellan EA, Medline A, Bird RP. (1991). Sequential analysis of the growth and morphological characteristics of aberrant crypt foci: putative preneoplastic lesions. Cancer Res, 51, 5270- 4.
24. Michael A Pereira, Leta H Barnes, Vicki L Rassman, Cary V Kelloff, E Steele. (1994). Use of azoxymethane - induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis, 15(5), 1049-1054.
25. Moncada S, Palmer RMJ, Higgs EA. (1991). Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev, 43, 109-41.
26. Moncada S, Higgs EA. (1995). Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEBJ, 9, 1319-30.
27. Moteki H, Hibasami H, Yamada Y, et al. (2002). Specific induction of apoptosis by 1, 8-cineole in two human leukemia cell lines, but not a in human stomach cancer cell line. Oncology Reports, 9, 757-60.
28. Ota S, Bamba H, Kato A, et al. (2002). Review Article: COX-2, prostanoids and colon cancer. Aliment Pharmacol Ther, 16 (Suppl), 102-6.
29. Pretlow TP, Barrow BJ, Ashton WS, et al. (1991). Aberrant crypts: Putative preneoplastic foci in human colonic mucosa. Cancer Res, 51, 1564-7.
30. Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA. (1992). Aberrant crypts in human colonic mucosa: putative preneoplastic lesions. J Cell Biochem, 16G (suppl), 55-62,.
31. Reddy BS, et al. (1997). Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res, 57, 420-5.
32. Ricchi P, Pignata S, Iaffaioli RV, Daniele BJ. (2003). Cyclooxygenase inhibition in colorectal adenomas and cancer. Clin Gastroenterol, 37, 281-7.
33. Ripple GH. (2000). Phase I clinical trial and pharmacokinetics study of perillyl alcohol administered four times a day. Clin Cancer Res, 6, 390-6.
34. Schimdt HHW, Lohmann SM, Walter U. (1993). The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta, 1178, 153-75.
35. Tao L, et al. (2002). Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short term treatment with chemopreventive agents. Carcinogenesis, 23, 1447-54.
36. Uedo N, et al. (1999). Inhibition by d-limonene of gastric carcinogenesis induced by N-methyl-N'- nitro-Nnitrosoguanidine in Wister rats. Cancer Lett, 137, 131-6.
37. Watanabe K, Kawamori T, Nakatsugi S, Wakabayashi K. (2000). COX-2 and iNOS, good targets for chemoprevention of colon cancer. Biofactors, 12, 129-33.
38. Yeole BB, et al. (2001). Population-based survival from colorectal cancer in Mumbai, (Bombay) India. Eur J Cancer, 37, 1402-8.